JPRN-UMIN000032308招募中未知
Efficacy of rifaximin for the treatment of hepatic encephalopathy through the intestinal permeability: an open-label, single-arm, singlecenter, pilot study - Efficacy of rifaximin for the treatment of hepatic encephalopathy through the intestinal permeability
Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan0 个研究点目标入组 30 人开始时间: 2018年4月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The patient with the change of the medicine for the hepatic encephalopathy within agreement acquisition three months ago. The patient who corresponds to a taboo listed in the attached document of rifaximine.
研究者
相似试验
进行中（未招募）
1 期
Administration of Rifaximin to improve liver regeneration and function after liver resectioPatients undergoing major liver resection will be included into the studyEUCTR2013-004644-28-DERWTH Aachen University, represented by the Rector, himself, represented by the Dean of the Medical Faculty96
已完成
不适用
The effect of rifaximin on liver cirrhosis patients with hepatic encephalopathyJPRN-UMIN000032548ara Medical University50
招募中
不适用
Efficacy and safety of Rifaximin for the treatment of liver cirrhosis with covert hepatic encephalopathyiver cirrhosisJPRN-UMIN000044657Wakayama Medical University40
进行中（未招募）
不适用
RiFL: Rifaxamin in Fatty Liver Disease.Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)? - Rifaximin in Fatty Liver v2.0EUCTR2010-021515-17-GBImperial College London
已完成
不适用
Efficacy of Rifaximin on Hepatosteatosis and Steatohepatitis PatientsSteatohepatitisFatty LiverNCT02009592Bezmialem Vakif University42